Ogino Takayuki, Komoike Yoshifumi, Ishitobi Masato, Motomura Kazuyoshi, Inaji Hideo, Koyama Hiroki
Dept. of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases.
Gan To Kagaku Ryoho. 2008 Nov;35(12):2234-6.
We report a long-term survival case of metastatic breast cancer treated with trastuzumab and paclitaxel. The patient was a 50-year-old female. She underwent left mastectomy with axillary lymphadenectomy for advanced breast cancer with liver metastases. Histological examination showed papillotublar carcinoma, f, T3, ly3, v2, N2 (24/34), histological grade III, ER (-), PgR (-), HER2 (3+). Trastuzumab and paclitaxel was performed. One year after the operation, any lesions of liver were not detected by CT and she was diagnosed as a complete response. No evidence of viable lesions has been found for 7 years. Breast cancer with liver metastases often could be a life threatening, and therefore an optimal chemotherapy should be applied as soon as possible. Trastuzumab and paclitaxel would be one of the optimal chemotherapies for HER2 positive breast cancer.
我们报告了一例接受曲妥珠单抗和紫杉醇治疗的转移性乳腺癌长期生存病例。患者为一名50岁女性。她因晚期乳腺癌伴肝转移接受了左乳房切除术及腋窝淋巴结清扫术。组织学检查显示为乳头管状癌,f,T3,ly3,v2,N2(24/34),组织学III级,雌激素受体(ER)(-),孕激素受体(PgR)(-),人表皮生长因子受体2(HER2)(3+)。给予曲妥珠单抗和紫杉醇治疗。术后一年,CT未检测到肝脏有任何病变,她被诊断为完全缓解。7年来未发现有存活病灶的证据。伴有肝转移的乳腺癌通常可能危及生命,因此应尽快应用最佳化疗方案。曲妥珠单抗和紫杉醇将是HER2阳性乳腺癌的最佳化疗方案之一。